Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Alzhemed missed the primary endpoints in a North American, double-blind, placebo-controlled Phase III trial in 1,052 patients.
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury